101 related articles for article (PubMed ID: 30575329)
41. The Journey for Lung Cancer Screening where we Stand Today.
Wahla AS; Zoumot Z; Uzbeck M; Mallat J; Souilamas R; Shafiq I
Open Respir Med J; 2022; 16():e187430642207060. PubMed ID: 37273952
[TBL] [Abstract][Full Text] [Related]
42. Potential for Urolithiasis-related Research Using the Novel Medicare-Litholink Database.
Krampe NA; Oerline MK; Asplin JR; Hsi RS; Crivelli JJ; Shahinian VB; Hollingsworth JM
Urol Pract; 2023 Mar; 10(2):147-152. PubMed ID: 37103409
[TBL] [Abstract][Full Text] [Related]
43. The Impact of Social Determinants of Health, Namely Financial Assistance, on Overall Survival in Advanced-Stage Non-Small Cell Lung Cancer Patients.
Bello A; Makani NS
Cureus; 2023 Mar; 15(3):e36355. PubMed ID: 37082487
[TBL] [Abstract][Full Text] [Related]
44. Risk Model-Based Lung Cancer Screening : A Cost-Effectiveness Analysis.
Toumazis I; Cao P; de Nijs K; Bastani M; Munshi V; Hemmati M; Ten Haaf K; Jeon J; Tammemägi M; Gazelle GS; Feuer EJ; Kong CY; Meza R; de Koning HJ; Plevritis SK; Han SS
Ann Intern Med; 2023 Mar; 176(3):320-332. PubMed ID: 36745885
[TBL] [Abstract][Full Text] [Related]
45. Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy.
Voruganti T; Soulos PR; Mamtani R; Presley CJ; Gross CP
JAMA Oncol; 2023 Mar; 9(3):334-341. PubMed ID: 36701150
[TBL] [Abstract][Full Text] [Related]
46. Machine Learning for Lung Cancer Diagnosis, Treatment, and Prognosis.
Li Y; Wu X; Yang P; Jiang G; Luo Y
Genomics Proteomics Bioinformatics; 2022 Oct; 20(5):850-866. PubMed ID: 36462630
[TBL] [Abstract][Full Text] [Related]
47. Cost-Effectiveness of a Telephone-Based Smoking Cessation Randomized Trial in the Lung Cancer Screening Setting.
Cao P; Smith L; Mandelblatt JS; Jeon J; Taylor KL; Zhao A; Levy DT; Williams RM; Meza R; Jayasekera J
JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35818125
[TBL] [Abstract][Full Text] [Related]
48. Osimertinib-Centered Therapy Against Uncommon Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer- A Mini Review.
Song C; Yang X
Front Oncol; 2022; 12():834585. PubMed ID: 35494059
[TBL] [Abstract][Full Text] [Related]
49. Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma.
Dong OM; Poonnen PJ; Winski D; Reed SD; Vashistha V; Bates J; Kelley MJ; Voora D
Value Health; 2022 Apr; 25(4):582-594. PubMed ID: 35365302
[TBL] [Abstract][Full Text] [Related]
50. Healthcare Utilization Disparities Among Lung Cancer Patients in US Hospitals During 2010-2014: Evidence from the US Hispanic Population's Hospital Charges and Length of Stay.
Kim SJ; Medina M; Delgado R; Miller A; Chang J
Int J Gen Med; 2022; 15():1329-1339. PubMed ID: 35173471
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness and health impact of lung cancer screening with low-dose computed tomography for never smokers in Japan and the United States: a modelling study.
Kowada A
BMC Pulm Med; 2022 Jan; 22(1):19. PubMed ID: 34996423
[TBL] [Abstract][Full Text] [Related]
52. A Cost-Effectiveness Analysis of Lung Cancer Screening With Low-Dose Computed Tomography and a Diagnostic Biomarker.
Toumazis I; Erdogan SA; Bastani M; Leung A; Plevritis SK
JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34738073
[TBL] [Abstract][Full Text] [Related]
53. Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives.
Cheng S; Pei R; Li J; Li B; Tang L; Yin T; Liu S
Ann Transl Med; 2021 Sep; 9(18):1481. PubMed ID: 34734033
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.
Toumazis I; de Nijs K; Cao P; Bastani M; Munshi V; Ten Haaf K; Jeon J; Gazelle GS; Feuer EJ; de Koning HJ; Meza R; Kong CY; Han SS; Plevritis SK
JAMA Oncol; 2021 Dec; 7(12):1833-1842. PubMed ID: 34673885
[TBL] [Abstract][Full Text] [Related]
55. Influence of respiratory function training under the mode of mutual-assisted patients on postoperative pulmonary infection and immune function on lung cancer.
He R; Zhu Q; Wang Y; Chen G; Chen S; Wang Y
Am J Transl Res; 2021; 13(8):9260-9268. PubMed ID: 34540042
[TBL] [Abstract][Full Text] [Related]
56. A direct method for the identification of patterns of care using administrative databases: the case of breast cancer.
Busco S; Tavilla A; Gigli A; Lopez T; Pierannunzio D; Mallone S; Guzzinati S; Capodaglio G; Giusti F; Angiolini C; Francisci S
Eur J Health Econ; 2021 Dec; 22(9):1477-1485. PubMed ID: 34312745
[TBL] [Abstract][Full Text] [Related]
57. Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
Li S; Li J; Peng L; Li Y; Wan X
Front Oncol; 2021; 11():684073. PubMed ID: 34136409
[TBL] [Abstract][Full Text] [Related]
58. Economic costs of terminal care for selected non-communicable diseases from a healthcare perspective: a review of mortality records from a tertiary hospital in Nigeria.
Olumide AO; Shmueli A; Omotade OO; Adebayo ES; Alonge TO; Ogun GO
BMJ Open; 2021 Apr; 11(4):e044969. PubMed ID: 33895715
[TBL] [Abstract][Full Text] [Related]
59. Cost-Effectiveness of Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Simulation Study.
Cadham CJ; Cao P; Jayasekera J; Taylor KL; Levy DT; Jeon J; Elkin EB; Foley KL; Joseph A; Kong CY; Minnix JA; Rigotti NA; Toll BA; Zeliadt SB; Meza R; Mandelblatt J;
J Natl Cancer Inst; 2021 Aug; 113(8):1065-1073. PubMed ID: 33484569
[TBL] [Abstract][Full Text] [Related]
60. Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model.
Buja A; Rivera M; De Polo A; Brino ED; Marchetti M; Scioni M; Pasello G; Bortolami A; Rebba V; Schiavon M; Calabrese F; Mandoliti G; Baldo V; Conte P
Thorac Cancer; 2021 Jan; 12(1):13-20. PubMed ID: 33219738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
